These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors. Gregus Z; Németi B Toxicol Sci; 2007 Nov; 100(1):44-53. PubMed ID: 17693424 [TBL] [Abstract][Full Text] [Related]
3. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Shapiro GI; Koestner DA; Matranga CB; Rollins BJ Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362 [TBL] [Abstract][Full Text] [Related]
4. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132 [TBL] [Abstract][Full Text] [Related]
5. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211 [TBL] [Abstract][Full Text] [Related]
6. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238 [TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Gojo I; Zhang B; Fenton RG Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644 [TBL] [Abstract][Full Text] [Related]
8. Rhabdoid tumor growth is inhibited by flavopiridol. Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228 [TBL] [Abstract][Full Text] [Related]
9. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol. Tsitsanou KE; Hayes JM; Keramioti M; Mamais M; Oikonomakos NG; Kato A; Leonidas DD; Zographos SE Food Chem Toxicol; 2013 Nov; 61():14-27. PubMed ID: 23279842 [TBL] [Abstract][Full Text] [Related]
10. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. de Azevedo WF; Canduri F; da Silveira NJ Biochem Biophys Res Commun; 2002 Apr; 293(1):566-71. PubMed ID: 12054639 [TBL] [Abstract][Full Text] [Related]
11. Flavopiridol binds to duplex DNA. Bible KC; Bible RH; Kottke TJ; Svingen PA; Xu K; Pang YP; Hajdu E; Kaufmann SH Cancer Res; 2000 May; 60(9):2419-28. PubMed ID: 10811119 [TBL] [Abstract][Full Text] [Related]
12. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. Oikonomakos NG; Schnier JB; Zographos SE; Skamnaki VT; Tsitsanou KE; Johnson LN J Biol Chem; 2000 Nov; 275(44):34566-73. PubMed ID: 10924512 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. Wang F; Corbett D; Osuga H; Osuga S; Ikeda JE; Slack RS; Hogan MJ; Hakim AM; Park DS J Cereb Blood Flow Metab; 2002 Feb; 22(2):171-82. PubMed ID: 11823715 [TBL] [Abstract][Full Text] [Related]
14. Modeling the biochemical differences between rabbit muscle and human liver phosphorylase. Rath VL; Newgard CB; Sprang SR; Goldsmith EJ; Fletterick RJ Proteins; 1987; 2(3):225-35. PubMed ID: 3447179 [TBL] [Abstract][Full Text] [Related]
15. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931 [TBL] [Abstract][Full Text] [Related]
16. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974 [TBL] [Abstract][Full Text] [Related]
17. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305 [TBL] [Abstract][Full Text] [Related]
18. Glutathione-dependent reduction of arsenate by glycogen phosphorylase a reaction coupled to glycogenolysis. Németi B; Gregus Z Toxicol Sci; 2007 Nov; 100(1):36-43. PubMed ID: 17693425 [TBL] [Abstract][Full Text] [Related]
19. Slow step in activation of muscle glycogen phosphorylase b by adenosine 5'-monophosphate. Kurganov BI; Schors EI; Klinov SV; Chebotareva NA Biochem Mol Biol Int; 1995 May; 36(1):155-61. PubMed ID: 7663410 [TBL] [Abstract][Full Text] [Related]
20. Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. Lerín C; Montell E; Nolasco T; García-Rocha M; Guinovart JJ; Gómez-Foix AM Biochem J; 2004 Mar; 378(Pt 3):1073-7. PubMed ID: 14651477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]